Company Monopar Therapeutics Inc.

Equities

MNPR

US61023L1089

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:21:07 2024-05-23 pm EDT			5-day change	1st Jan Change
0.625 ^USD	+1.69%		+1.05%	+83.42%

May. 09	Monopar Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 16	Monopar Therapeutics Files Provisional Patent for New MNPR-101 Construct	MT

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.

Number of employees: 10

Managers	Title	Age	Since
Chandler Robinson FOU	Founder	40	14-11-30
Kim Tsuchimoto DFI	Director of Finance/CFO	61	15-05-31
Laura Kelly CTO	Chief Tech/Sci/R&D Officer	-	21-02-17
Andrew Cittadine COO	Chief Operating Officer	52	21-05-31
Patrice Rioux CTO	Chief Tech/Sci/R&D Officer	73	16-11-30

Members of the board	Title	Age	Since
Michael Brown BRD	Director/Board Member	67	14-11-30
Arthur Klausner BRD	Director/Board Member	64	17-07-31
Kim Tsuchimoto DFI	Director of Finance/CFO	61	15-05-31
Christopher Starr FOU	Founder	71	14-11-30
Raymond Anderson BRD	Director/Board Member	82	17-03-31
Chandler Robinson FOU	Founder	40	14-11-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	17,484,175	8,346,214 ( 47.74 %)	0	47.74 %

Name	Equities	%	Valuation
Tacticgem LLC 41.06 %	7,166,667	41.06 %	4 M $
Jeffrey Klunzinger 3.969 %	692,800	3.969 %	434 386 $
Michael Brown 1.351 %	235,863	1.351 %	147 886 $
Millennium Management LLC 1.102 %	192,381	1.102 %	120 623 $
Chandler Robinson 0.9518 %	166,131	0.9518 %	104 164 $
Christopher Starr 0.4312 %	75,263	0.4312 %	47 190 $
Andrew Cittadine 0.3301 %	57,624	0.3301 %	36 130 $
Kim Tsuchimoto 0.2891 %	50,470	0.2891 %	31 645 $
Vanguard Group, Inc. (Subfiler) 0.2588 %	45,167	0.2588 %	28 320 $
Geode Capital Management LLC 0.2360 %	41,199	0.2360 %	25 832 $

Monopar Therapeutics, Inc.

1000 Skokie Boulevard Suite 350

60091, Wilmette

+847 388 0349

http://www.monopartx.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.6146 USD

Average target price

2.08 USD

Spread / Average Target

+238.43%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MONOPAR THERAPEUTICS INC.	+83.42%	10.73M
MODERNA, INC.	+64.40%	62.59B
IQVIA HOLDINGS INC.	-1.98%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.93%	27.9B
ICON PUBLIC LIMITED COMPANY	+12.43%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-22.14%	19.09B
BIO-TECHNE CORPORATION	+3.84%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.49%	12.26B
MEDPACE HOLDINGS, INC.	+27.17%	12.05B

Other Biotechnology & Medical Research